Antibe Therapeutics (ATBPF) Short Interest Ratio & Short Volume $0.22 0.00 (0.00%) As of 03/31/2025 Add Compare Share Share Short Interest Stock AnalysisChartShort InterestBuy This Stock Antibe Therapeutics Short Interest DataAntibe Therapeutics (ATBPF) has a short interest of 8,600 shares, representing 0.02% of the float (the number of shares available for trading by the public). This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 27,352 shares to cover all short positions.Current Short Interest8,600 sharesPrevious Short Interest8,600 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$1,854.16Short Interest Ratio0.0 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares52,981,000 sharesShort Percent of Float0.02%Today's Trading Volume0 sharesAverage Trading Volume27,352 sharesToday's Volume Vs. Average0% Short Selling Antibe Therapeutics? Sign up to receive the latest short interest report for Antibe Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATBPF Short Interest Over TimeATBPF Days to Cover Over TimeATBPF Percentage of Float Shorted Over Time Remove Ads Antibe Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20258,600 shares $1,854.16 No Change0.0%0 $0.22 2/28/20258,600 shares $1,854.16 No Change0.0%0 $0.22 2/15/20258,600 shares $1,854.16 No Change0.0%0 $0.22 1/31/20258,600 shares $1,854.16 -86.8%N/A0 $0.22 1/15/202565,100 shares $14,035.56 No ChangeN/A0 $0.22 12/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 12/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 11/30/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 11/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 10/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 Get the Latest News and Ratings for ATBPF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 8/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 8/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 6/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 6/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 4/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 4/15/202465,100 shares $14,035.56 +1,934.4%N/A0.7 $0.22 3/31/20243,200 shares $1,070.40 -64.0%N/A0.1 $0.33 3/15/20248,900 shares $2,891.61 -73.1%N/A0.1 $0.32 2/29/202433,100 shares $23,653.26 +234.3%N/A0.5 $0.71 2/15/20249,900 shares $6,811.20 No ChangeN/A0.6 $0.69 1/15/202410,400 shares $8,112.00 -9.6%N/A1.4 $0.78 12/31/202311,500 shares $7,843.00 +121.2%N/A0.7 $0.68 12/15/20235,200 shares $3,571.88 -17.5%N/A1.1 $0.69 11/30/20236,300 shares $3,433.50 -54.0%N/A0.8 $0.55 11/15/202313,700 shares $7,521.30 +17.1%N/A0.1 $0.55 10/31/202311,700 shares $5,382.00 -27.8%N/A0.2 $0.46 10/15/202316,200 shares $5,799.60 +211.5%N/A1.7 $0.36 9/30/20235,200 shares $1,863.06 -24.6%N/A0.2 $0.36 9/15/20236,900 shares $2,829.00 -76.4%N/A0.3 $0.41 8/31/202329,200 shares $11,554.44 -22.8%N/A1.1 $0.40 8/15/202337,800 shares $15,498.00 +563.2%N/A1.5 $0.41 7/31/20235,700 shares $2,053.14 -8.1%N/A0.4 $0.36 7/15/20236,200 shares $2,156.98 No ChangeN/A2.8 $0.35Trump’s Final Plan (Ad)Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.Click here for the full story. 6/30/20236,200 shares $2,170.00 -7.5%N/A2.6 $0.35 6/15/20236,700 shares $2,517.19 -71.7%N/A1.6 $0.38 5/31/202323,700 shares $8,752.41 +203.9%N/A1.3 $0.37 5/15/20237,800 shares $2,934.36 -27.8%N/A0.6 $0.38 4/30/202310,800 shares $4,342.68 -6.9%N/A3.1 $0.40 4/15/202311,600 shares $4,637.68 -78.6%N/A3.6 $0.40 3/31/202354,100 shares $23,766.13 -1.3%N/A2.5 $0.44 3/15/202354,800 shares $20,643.16 +260.5%N/A1.2 $0.38 2/28/202315,200 shares $5,668.08 -37.5%N/A1.7 $0.37 2/15/202324,300 shares $10,529.19 +22.7%N/A4.9 $0.43 1/31/202319,800 shares $8,401.14 +94.1%N/A0.8 $0.42 1/15/202310,200 shares $5,115.81 -56.8%N/A4.3 $0.50 12/30/202223,600 shares $7,622.80 -23.1%N/A2.5 $0.32 12/15/202230,700 shares $11,666.00 +44.8%N/A2.8 $0.38 11/30/202221,200 shares $7,420.00 +32.5%N/A3.2 $0.35 11/15/202216,000 shares $5,912.00 +3.9%N/A1.3 $0.37 10/31/202215,400 shares $5,998.30 +12.4%N/A3.1 $0.39 10/15/202213,700 shares $5,555.35 -8.7%N/A3 $0.41 9/30/202215,000 shares $6,718.50 -41.4%N/A1.1 $0.45 9/15/202225,600 shares $12,170.24 -13.8%N/A2.8 $0.48 8/31/202229,700 shares $14,362.92 -15.1%N/A2.3 $0.48 8/15/202235,000 shares $17,570.00 -39.2%N/A3.3 $0.50 7/31/202257,600 shares $25,920.00 -26.9%N/A20.6 $0.45 7/15/202278,800 shares $37,248.76 +3.8%N/A17.1 $0.47 6/30/202275,900 shares $35,832.39 -5.8%N/A5.2 $0.47 6/15/202280,600 shares $38,833.08 +2.8%N/A6.3 $0.48 5/31/202278,400 shares $42,696.64 +5.0%N/A6.2 $0.54 5/15/202274,700 shares $39,591.00 +48.8%N/A6.2 $0.53 4/30/202250,200 shares $28,011.60 +8.9%N/A7 $0.56 4/15/202246,100 shares $27,293.51 +45.9%N/A3.7 $0.59 3/31/202231,600 shares $20,066.00 +3.3%N/A2.4 $0.64 3/15/202230,600 shares $17,448.12 -23.7%N/A1.6 $0.57 2/28/202240,100 shares $23,454.49 +74.4%N/A1.1 $0.58 2/15/202223,000 shares $12,811.00 +57.5%N/A1.5 $0.56 1/31/202214,600 shares $7,678.14 +630.0%N/A0.2 $0.53 1/15/20222,000 shares $1,115.80 -66.1%N/A0.1 $0.56 12/31/20215,900 shares $3,043.81 -65.7%N/A0.1 $0.52 12/15/202117,200 shares $8,536.36 -71.4%N/A0.4 $0.50 11/30/202160,100 shares $32,737.67 -41.1%N/A1.6 $0.54 11/15/2021102,000 shares $72,644.40 -42.3%N/A0.7 $0.71 10/29/2021176,800 shares $114,725.52 +665.4%N/A1.2 $0.65 10/15/202123,100 shares $18,225.90 +725.0%N/A0.4 $0.79 9/30/20212,800 shares $2,640.40 +180.0%N/A0 $0.94 9/15/20211,000 shares $948.40 +11.1%N/A0 $0.95 8/31/2021900 shares $900.00 -96.4%N/A0 $1.00 8/13/202124,700 shares $25,935.00 -88.2%N/A0.1 $1.05 7/30/2021208,400 shares $561,638.00 +10.7%N/A6.6 $2.70 7/15/2021188,200 shares $513,409.60 -0.1%N/A9.6 $2.73 6/30/2021188,300 shares $559,251.00 -3.7%N/A5.8 $2.97 6/15/2021195,500 shares $602,218.20 -8.2%N/A5.5 $3.08Trump’s Final Plan (Ad)Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.Click here for the full story. 5/28/2021212,900 shares $724,924.50 +8.0%N/A11 $3.41 5/14/2021197,200 shares $646,816.00 -5.6%N/A8.2 $3.28 4/30/2021208,900 shares $714,458.89 +6.8%N/A5.8 $3.42 4/15/2021195,600 shares $708,072.00 -12.6%N/A9.5 $3.62 3/31/2021223,700 shares $883,615.00 +41.5%N/A1.8 $3.95 3/15/2021158,100 shares $623,388.30 -54.4%N/A3.2 $3.94 2/26/2021346,600 shares $1.50 million +439.9%N/A2 $4.34 2/12/202164,200 shares $301,098.00 -17.3%N/A0.5 $4.69 1/29/202177,600 shares $219,297.60 +21.1%N/A1.8 $2.83 12/31/202028,600 shares $89,518.00 No ChangeN/A0.5 $3.13 11/30/202030,700 shares $9,513.93 +332.4%N/A0.1 $0.31 11/15/20207,100 shares $2,188.93 -64.5%N/A0.1 $0.31 10/30/202020,000 shares $4,800.00 No ChangeN/A0.2 $0.24 10/15/202020,000 shares $5,342.00 +52.7%N/A0.2 $0.27 9/30/202013,100 shares $3,445.30 No ChangeN/A0 $0.26 8/31/20201,300 shares $388.96 -93.1%N/A0 $0.30 8/14/202018,900 shares $5,934.60 -44.9%N/A0 $0.31 7/31/202034,300 shares $9,569.70 +2,350.0%N/A0.1 $0.28 7/15/20201,400 shares $408.52 -92.4%N/A0 $0.29 6/30/202018,300 shares $5,574.18 -36.2%N/A0 $0.30 6/15/202028,700 shares $10,705.10 +135.3%N/A0 $0.37 5/29/202012,200 shares $3,782.00 +281.3%N/A0.1 $0.31 5/15/20203,200 shares $1,856.00 -98.3%N/A0 $0.58 4/30/2020191,600 shares $101,548.00 +787.0%N/A0.6 $0.53 4/15/202021,600 shares $10,584.00 -83.4%N/A0.1 $0.49 ATBPF Short Interest - Frequently Asked Questions What is Antibe Therapeutics' current short interest? Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 8,600 shares of ATBPF short. 0.02% of Antibe Therapeutics' shares are currently sold short. Learn More on Antibe Therapeutics' current short interest. What is a good short interest percentage for Antibe Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.02% of Antibe Therapeutics' floating shares are currently sold short. How does Antibe Therapeutics' short interest compare to its competitors? 0.02% of Antibe Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Antibe Therapeutics: Connect Biopharma Holdings Limited (0.02%), Karyopharm Therapeutics Inc. (13.63%), Repare Therapeutics Inc. (3.28%), Provectus Biopharmaceuticals, Inc. (0.00%), MAIA Biotechnology, Inc. (3.29%), Barinthus Biotherapeutics plc (0.04%), KALA BIO, Inc. (5.49%), Lantern Pharma Inc. (2.98%), Verrica Pharmaceuticals Inc. (8.48%), SCYNEXIS, Inc. (1.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Antibe Therapeutics stock? Short selling ATBPF is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Antibe Therapeutics? A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPF, which in turn drives the price of the stock up even further. How often is Antibe Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPF, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies Connect Biopharma Short Interest Data Karyopharm Therapeutics Short Interest Data Repare Therapeutics Short Interest Data Provectus Biopharmaceuticals Short Interest Data MAIA Biotechnology Short Interest Data Barinthus Biotherapeutics Short Interest Data KALA BIO Short Interest Data Lantern Pharma Short Interest Data Verrica Pharmaceuticals Short Interest Data SCYNEXIS Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ATBPF) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
